Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01209533 · ClinicalTrials.gov registry record · Early Phase 1

Inhaled Iloprost in Mild Asthma

A Early Phase 1 study, sponsored by Vanderbilt University.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target

NCT01209533 is a Early Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01209533, a Early Phase 1 study, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The purpose of the study is to determine if inhaled iloprost given four times daily can improve symptoms and lung function in adults with mild asthma.

Interventions

  • DRUG Iloprost

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-09
Est. Completion 2011-07
Phase Early Phase 1

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT01209533

The ClinicalTrials.gov registry entry for NCT01209533 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Iloprost is the first listed.

NCT01209533 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01209533 about?

NCT01209533 is a clinical study titled "Inhaled Iloprost in Mild Asthma". The purpose of the study is to determine if inhaled iloprost given four times daily can improve symptoms and lung function in adults with mild asthma.

What is the current status of trial NCT01209533?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2010-09. Estimated completion is 2011-07.

What interventions are being tested in trial NCT01209533?

The interventions under investigation include: Iloprost (DRUG).

Who is sponsoring clinical trial NCT01209533?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.